Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>(2<i>R</i>,3<i>S</i>)‐<i>N</i>‐tert‐Butoxycarbonyl‐3‐amino‐1‐chloro‐2‐hydroxy‐4‐phenylbutane (1b) is key for the synthesis of the antiviral drug atazanavir. It can be obtained via the stereoselective bioreduction of (3<i>S</i>)‐3‐(<i>N</i>‐Boc‐amino)‐1‐chloro‐4‐phenyl‐butanone (1a) with short‐chain dehydrogenase/reductase (SDR)(EC 1.1.1.1). To develop a practical and cost‐effective biocatalytic approach with high stability and reusability, an SDR mutant (muSDR) from <i>Novosphingobium aromaticivorans</i> was overexpressed in <i>Escherichia coli</i> cell and immobilized by cross‐linked enzyme aggregates with enhanced stability and high efficiency. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>muSDR gene was successfully cloned and overexpressed in <i>Escherichia coli</i> and reduced 1a to 1b with high stereoselectivity. Four resin‐bound muSDR and cross‐linked muSDR aggregates (muSDR‐CLEAs) were prepared and compared. With addition of Tween‐80, the muSDR‐CLEAs demonstrated much higher activity recovery than resin‐bound muSDR. Compared with free enzyme, muSDR‐CLEAs demonstrated enhanced thermal, pH, and storage stabilities and could obtain 1b with high substrate concentration, high <i>de</i>, and complete conversion. The reusability of CLEAs was also determined as no significant activity loss was observed after seven batches of reactions. The space time yield of the bioreduction using muSDR‐CLEAs was 226.6 g∙L<sup>‐1</sup>∙d<sup>‐1</sup>. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Overexpressed muSDR was efficiently immobilized, and it demonstrated superior stability and reusability. The recombinant muSDR and muSDR‐CLEAs are practical potential biocatalysts for industrial production of the atazanavir precursor.</p><p>This article is protected by copyright. All rights reserved.</p></section>

Improvement of the C -glycosylation Step for the Synthesis of Remdesivir

Weinreb Amide Approach To The Practical Synthesis Of A Key Remdesivir Intermediate

Direct and Catalytic C-Glycosylation of Arenes: Expeditious Synthesis of the Remdesivir Nucleoside

Synthesis of Remdesivir by Direct Lithiation of Pyrrolo[2,1‐f][1,2,4]triazine Derivatives Enabled C‐Glycosylation

Improved Synthesis of 1-[Hexahydrocyclopenta[c]pyrrol-2(1h)-yl]-3-(4-methylbenzenesulfonyl)ure A

Continuous-Flow Synthesis of the Nucleobase Unit of Remdesivir

Improved Synthesis of Cidofovir

An Improved Glycal Diazidation Protocol with Copper Catalysis

Chemical Synthesis of the Anti‐COVID‐19 Drug Remdesivir

Catalytic Asymmetric Synthesis of the anti-COVID-19 Drug Remdesivir

1′-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication

Optimized Synthesis of Anti-Covid-19 Drugs Aided by Retrosynthesis Software

Efficient synthesis of an antiviral drug intermediate using overexpressed short‐chain dehydrogenase and cross‐linked enzyme aggregates stabilization

Development of a Large-Scale Cyanation Process Using Continuous Flow Chemistry En Route to the Synthesis of Remdesivir

Expedient Synthesis of Antiviral Drug Molnupiravir from D-Ribose and Cytosine

A New Method to Synthesize Famciclovir

Improved Procedure for Synthesis of 2-Amino-6-chloro-9-β-d-ribofuranosylpurine

Advance of Structural Modification of Nucleosides Scaffold

1’-cyano substitution of Remdesivir “template-dependent” inhibiting the transcription of SARS-CoV-2

Development of a Synthesis Process for a Novel HCV NS5A Inhibitor, Emitasvir

Imp Roved Synthesis of Raltegravir